Global Perspectives in Atrial Fibrillation and Venous Thromboembolism: Reassessing the Role of NOAC Treatment in Special PopulationsPremiere Date: Monday, November 8, 2021
This activity offers CE credit for:%>
- Medicine (accme)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, November 8, 2022
|Gregory Lip, MD, FRCP, DFM, FACC, FESC, FEHRA (Moderator)
Price-Evans Chair of Cardiovascular Medicine
Director of the Liverpool Centre for Cardiovascular Science
University of Liverpool
|Jan Steffel, MD, FESC, FEHRA, FHRS
Professor of Cardiology, University of Zurich
Senior Consultant, Electrophysiology and Cardiac Devices
Hirslanden HeartClinic Zurich
Chair, Education Committee, European Heart Rhythm Association (EHRA)
Over the past decade, non-vitamin K antagonist oral anticoagulants (NOACs) have emerged as a preferred means of anticoagulation therapy to prevent stroke in atrial fibrillation (AF) and to manage venous thromboembolism (VTE). As clinical trial data and real-world experience have accrued, an expanding role for NOACs presents clinicians with increasingly complex decisions regarding selection of an appropriate agent, how long to sustain treatment, and when to use NOACs in special populations (e.g., elderly patients, patients with obesity, patients undergoing ablation, patients with cancer).
In this CME Outfitters webcast, two experts in cardiovascular disease and electrophysiology discuss practical scenarios for optimizing treatment with NOACs in the context of current guideline recommendations, including the 2021 European Heart Rhythm Association Practical Guide on the Use of NOACs in Patients with AF.
At the end of this CE activity, participants should be able to:
- Employ NOACs in the evidence-based care of patients requiring anticoagulation for AF and/or VTE, including patients in special populations.
- Implement guidelines and best practices to balance anticoagulation with CAD and cardiac peripheral procedures.
- Apply NOACs for anticoagulation in appropriate patients with cancer and associated comorbidities.
Supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.
Cardiologists, interventional cardiologists, oncologists, GPs, emergency department physicians, VTE specialists, hematologists, pulmonologists, nurse practitioners, PAs, and pharmacists
Note to Physicians:
Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 2 CreditTM toward their credit requirements. CME Outfitters is based in Bethesda, Maryland, USA. Please retain your certificate as proof of completion.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr Lip reports the following financial relationships:
Consultant/Speakers Bureau: (No fees received personally) Bristol Myers Squibb-Pfizer Alliance; Boehringer Ingelheim International; and Daiichi Sankyo Company
Dr Steffel reports the following financial relationships:
Consultant: Abbott; Alexion Pharmaceuticals, Inc.; Amgen Inc.; AstraZeneca; Bayer; Berlin-Chemie; Biosense Webster, Inc.; Biotronik, Inc.; Boehringer Ingelheim International; Boston Scientific Corporation; Bristol Myers Squibb Company; Daiichi Sankyo Company; Medtronic; Merck & Co., Inc./Merck Sharp & Dohme Corp (MSD); Novartis; Pfizer Inc.; Portola; Roche Diagnostics; SAJA Pharmaceuticals; Servier Laboratories; and WebMD LLC
Grants: (Paid to University of Zurich) Abbott; Bayer Healthcare; Biosense Webster, Inc.; Biotronik, Inc.; Boston Scientific Corporation; Daiichi Sankyo Company; and Medtronic
Other financial or material support: Ownership of CorXL
Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer) has no disclosures to report.
Warren Beckman (planning committee) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).